Reduction of circulating FABP4 level by treatment with omega-3 fatty acid ethyl esters

Masato Furuhashi, Shinya Hiramitsu, Tomohiro Mita, Akina Omori, Takahiro Fuseya, Shutaro Ishimura, Yuki Watanabe, Kyoko Hoshina, Megumi Matsumoto, Marenao Tanaka, Norihito Moniwa, Hideaki Yoshida, Junichi Ishii, Tetsuji Miura

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Fatty acid-binding protein 4 (FABP4/A-FABP/aP2) mainly expressed in adipocytes is secreted and acts as an adipokine. Increased circulating FABP4 level is associated with obesity, insulin resistance and atherosclerosis. However, little is known about the modulation of serum FABP4 level by drugs including anti-dyslipidemic agents. Methods: Patients with dyslipidemia were treated with omega-3 fatty acid ethyl esters (4 g/day; n = 14) containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for 4 weeks. Serum FABP4 level was measured before and after treatment. Expression and secretion of FABP4 were also examined in mouse 3T3-L1 adipocytes treated with EPA or DHA. Results: Treatment with omega-3 fatty acid ethyl esters significantly decreased triglycerides and serum FABP4 level (13.5 ± 1.5 vs. 11.5 ± 1.1 ng/ml, P = 0.017). Change in FABP4 level by omega-3 fatty acids was negatively correlated with change in levels of EPA + DHA (r = -0.643, P = 0.013), EPA (r = -0.540, P = 0.046) and DHA (r = -0.650, P = 0.011) but not change in the level of triglycerides or other fatty acid composition. Treatment of 3T3-L1 adipocytes with EPA or DHA had no effect on short-term (2 h) secretion of FABP4. However, gene expression and long-term (24 h) secretion of FABP4 were significantly reduced by treatment with EPA or DHA. Conclusions: Omega-3 fatty acids decrease circulating FABP4 level, possibly by reducing expression and consecutive secretion of FABP4 in adipocytes. Reducing FABP4 level might be involved in suppression of cardiovascular events by omega-3 fatty acids.

Original languageEnglish
Article number5
JournalLipids in Health and Disease
Volume15
Issue number1
DOIs
Publication statusPublished - 12-01-2016

Fingerprint

Eicosapentaenoic Acid
Docosahexaenoic Acids
Omega-3 Fatty Acids
Esters
Adipocytes
Triglycerides
Therapeutics
Serum
Fatty Acid-Binding Proteins
Adipokines
Dyslipidemias
Gene expression
Insulin Resistance
Atherosclerosis
Fatty Acids
Obesity
Modulation
Insulin
Gene Expression
Chemical analysis

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Furuhashi, M., Hiramitsu, S., Mita, T., Omori, A., Fuseya, T., Ishimura, S., ... Miura, T. (2016). Reduction of circulating FABP4 level by treatment with omega-3 fatty acid ethyl esters. Lipids in Health and Disease, 15(1), [5]. https://doi.org/10.1186/s12944-016-0177-8
Furuhashi, Masato ; Hiramitsu, Shinya ; Mita, Tomohiro ; Omori, Akina ; Fuseya, Takahiro ; Ishimura, Shutaro ; Watanabe, Yuki ; Hoshina, Kyoko ; Matsumoto, Megumi ; Tanaka, Marenao ; Moniwa, Norihito ; Yoshida, Hideaki ; Ishii, Junichi ; Miura, Tetsuji. / Reduction of circulating FABP4 level by treatment with omega-3 fatty acid ethyl esters. In: Lipids in Health and Disease. 2016 ; Vol. 15, No. 1.
@article{cb237607bfef4344834d7b551f7ceed5,
title = "Reduction of circulating FABP4 level by treatment with omega-3 fatty acid ethyl esters",
abstract = "Background: Fatty acid-binding protein 4 (FABP4/A-FABP/aP2) mainly expressed in adipocytes is secreted and acts as an adipokine. Increased circulating FABP4 level is associated with obesity, insulin resistance and atherosclerosis. However, little is known about the modulation of serum FABP4 level by drugs including anti-dyslipidemic agents. Methods: Patients with dyslipidemia were treated with omega-3 fatty acid ethyl esters (4 g/day; n = 14) containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for 4 weeks. Serum FABP4 level was measured before and after treatment. Expression and secretion of FABP4 were also examined in mouse 3T3-L1 adipocytes treated with EPA or DHA. Results: Treatment with omega-3 fatty acid ethyl esters significantly decreased triglycerides and serum FABP4 level (13.5 ± 1.5 vs. 11.5 ± 1.1 ng/ml, P = 0.017). Change in FABP4 level by omega-3 fatty acids was negatively correlated with change in levels of EPA + DHA (r = -0.643, P = 0.013), EPA (r = -0.540, P = 0.046) and DHA (r = -0.650, P = 0.011) but not change in the level of triglycerides or other fatty acid composition. Treatment of 3T3-L1 adipocytes with EPA or DHA had no effect on short-term (2 h) secretion of FABP4. However, gene expression and long-term (24 h) secretion of FABP4 were significantly reduced by treatment with EPA or DHA. Conclusions: Omega-3 fatty acids decrease circulating FABP4 level, possibly by reducing expression and consecutive secretion of FABP4 in adipocytes. Reducing FABP4 level might be involved in suppression of cardiovascular events by omega-3 fatty acids.",
author = "Masato Furuhashi and Shinya Hiramitsu and Tomohiro Mita and Akina Omori and Takahiro Fuseya and Shutaro Ishimura and Yuki Watanabe and Kyoko Hoshina and Megumi Matsumoto and Marenao Tanaka and Norihito Moniwa and Hideaki Yoshida and Junichi Ishii and Tetsuji Miura",
year = "2016",
month = "1",
day = "12",
doi = "10.1186/s12944-016-0177-8",
language = "English",
volume = "15",
journal = "Lipids in Health and Disease",
issn = "1476-511X",
publisher = "BioMed Central",
number = "1",

}

Furuhashi, M, Hiramitsu, S, Mita, T, Omori, A, Fuseya, T, Ishimura, S, Watanabe, Y, Hoshina, K, Matsumoto, M, Tanaka, M, Moniwa, N, Yoshida, H, Ishii, J & Miura, T 2016, 'Reduction of circulating FABP4 level by treatment with omega-3 fatty acid ethyl esters', Lipids in Health and Disease, vol. 15, no. 1, 5. https://doi.org/10.1186/s12944-016-0177-8

Reduction of circulating FABP4 level by treatment with omega-3 fatty acid ethyl esters. / Furuhashi, Masato; Hiramitsu, Shinya; Mita, Tomohiro; Omori, Akina; Fuseya, Takahiro; Ishimura, Shutaro; Watanabe, Yuki; Hoshina, Kyoko; Matsumoto, Megumi; Tanaka, Marenao; Moniwa, Norihito; Yoshida, Hideaki; Ishii, Junichi; Miura, Tetsuji.

In: Lipids in Health and Disease, Vol. 15, No. 1, 5, 12.01.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Reduction of circulating FABP4 level by treatment with omega-3 fatty acid ethyl esters

AU - Furuhashi, Masato

AU - Hiramitsu, Shinya

AU - Mita, Tomohiro

AU - Omori, Akina

AU - Fuseya, Takahiro

AU - Ishimura, Shutaro

AU - Watanabe, Yuki

AU - Hoshina, Kyoko

AU - Matsumoto, Megumi

AU - Tanaka, Marenao

AU - Moniwa, Norihito

AU - Yoshida, Hideaki

AU - Ishii, Junichi

AU - Miura, Tetsuji

PY - 2016/1/12

Y1 - 2016/1/12

N2 - Background: Fatty acid-binding protein 4 (FABP4/A-FABP/aP2) mainly expressed in adipocytes is secreted and acts as an adipokine. Increased circulating FABP4 level is associated with obesity, insulin resistance and atherosclerosis. However, little is known about the modulation of serum FABP4 level by drugs including anti-dyslipidemic agents. Methods: Patients with dyslipidemia were treated with omega-3 fatty acid ethyl esters (4 g/day; n = 14) containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for 4 weeks. Serum FABP4 level was measured before and after treatment. Expression and secretion of FABP4 were also examined in mouse 3T3-L1 adipocytes treated with EPA or DHA. Results: Treatment with omega-3 fatty acid ethyl esters significantly decreased triglycerides and serum FABP4 level (13.5 ± 1.5 vs. 11.5 ± 1.1 ng/ml, P = 0.017). Change in FABP4 level by omega-3 fatty acids was negatively correlated with change in levels of EPA + DHA (r = -0.643, P = 0.013), EPA (r = -0.540, P = 0.046) and DHA (r = -0.650, P = 0.011) but not change in the level of triglycerides or other fatty acid composition. Treatment of 3T3-L1 adipocytes with EPA or DHA had no effect on short-term (2 h) secretion of FABP4. However, gene expression and long-term (24 h) secretion of FABP4 were significantly reduced by treatment with EPA or DHA. Conclusions: Omega-3 fatty acids decrease circulating FABP4 level, possibly by reducing expression and consecutive secretion of FABP4 in adipocytes. Reducing FABP4 level might be involved in suppression of cardiovascular events by omega-3 fatty acids.

AB - Background: Fatty acid-binding protein 4 (FABP4/A-FABP/aP2) mainly expressed in adipocytes is secreted and acts as an adipokine. Increased circulating FABP4 level is associated with obesity, insulin resistance and atherosclerosis. However, little is known about the modulation of serum FABP4 level by drugs including anti-dyslipidemic agents. Methods: Patients with dyslipidemia were treated with omega-3 fatty acid ethyl esters (4 g/day; n = 14) containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for 4 weeks. Serum FABP4 level was measured before and after treatment. Expression and secretion of FABP4 were also examined in mouse 3T3-L1 adipocytes treated with EPA or DHA. Results: Treatment with omega-3 fatty acid ethyl esters significantly decreased triglycerides and serum FABP4 level (13.5 ± 1.5 vs. 11.5 ± 1.1 ng/ml, P = 0.017). Change in FABP4 level by omega-3 fatty acids was negatively correlated with change in levels of EPA + DHA (r = -0.643, P = 0.013), EPA (r = -0.540, P = 0.046) and DHA (r = -0.650, P = 0.011) but not change in the level of triglycerides or other fatty acid composition. Treatment of 3T3-L1 adipocytes with EPA or DHA had no effect on short-term (2 h) secretion of FABP4. However, gene expression and long-term (24 h) secretion of FABP4 were significantly reduced by treatment with EPA or DHA. Conclusions: Omega-3 fatty acids decrease circulating FABP4 level, possibly by reducing expression and consecutive secretion of FABP4 in adipocytes. Reducing FABP4 level might be involved in suppression of cardiovascular events by omega-3 fatty acids.

UR - http://www.scopus.com/inward/record.url?scp=84954178145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954178145&partnerID=8YFLogxK

U2 - 10.1186/s12944-016-0177-8

DO - 10.1186/s12944-016-0177-8

M3 - Article

C2 - 26754658

AN - SCOPUS:84954178145

VL - 15

JO - Lipids in Health and Disease

JF - Lipids in Health and Disease

SN - 1476-511X

IS - 1

M1 - 5

ER -